NEW YORK, NY – For decades, the role of regulatory T (Treg) cells in colorectal cancer has presented a perplexing paradox to the scientific community. While these immune cells are widely known to act as suppressors of the immune system, often hindering the body’s ability to combat most solid tumors, their abundance in colorectal cancer has surprisingly been linked to improved patient survival. This enigmatic exception has long defied explanation, posing a significant hurdle in the development of effective immunotherapies for this widespread and deadly disease.
Now, a groundbreaking study from the distinguished researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has finally unravelled this mystery. Published in the esteemed scientific journal Immunity, the findings reveal that Treg cells are not a monolithic entity but rather comprise two distinct subtypes with diametrically opposed functions within colorectal tumors. This pivotal discovery not only provides a clear explanation for the long-standing paradox but also opens promising new avenues for improving immunotherapy, particularly for the most common forms of colorectal cancer, and potentially for other cancers arising in barrier tissues such as the skin, stomach, mouth, and throat.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and Chair of the Immunology Program at MSK, and a Howard Hughes Medical Institute Investigator. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches in treatment."
This revelation represents a significant leap forward in understanding the intricate immune landscape of cancer and underscores the critical importance of moving beyond simplistic categorizations of immune cell populations.
Decades of Research Culminate in a Breakthrough
This landmark investigation is the culmination of more than two decades of pioneering research led by Dr. Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His extensive work has been instrumental in establishing the fundamental understanding of Treg cells’ role in maintaining "immune tolerance." This vital function allows the immune system to accurately distinguish between genuine harmful threats, such as pathogens, and harmless elements, like the body’s own cells, beneficial microbes, and everyday foods. By preventing misguided attacks on these harmless targets, Treg cells safeguard the body from autoimmune diseases and chronic inflammation.
Over the years, Dr. Rudensky’s laboratory has systematically deconstructed the biology of Treg cells, uncovering the intricate mechanisms governing their creation, their diverse functions, and their profound influence on various physiological processes, including the complex development of cancer. This latest study meticulously builds upon this rich foundation of knowledge, demonstrating how a deeper understanding of Treg cell heterogeneity can unlock novel therapeutic strategies.
The study was expertly led by a collaborative team of first authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now contributing to research at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who served as the study’s other senior author. Their combined expertise in immunology, oncology, and computational biology proved indispensable in navigating the complexities of this research.
Focusing on the Most Common and Challenging Form of Colorectal Cancer
Colorectal cancer remains a formidable public health challenge. According to the American Cancer Society, when considering both men and women, it ranks as the second leading cause of cancer-related death, highlighting the urgent need for more effective treatments.
A critical aspect of this study was its precise focus on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all colorectal cancer cases. Tumors in this category are characterized by relatively stable DNA, a feature that, unfortunately, correlates with a poor response to standard checkpoint inhibitor immunotherapies. This contrasts sharply with cancers exhibiting high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd), which, as earlier research at MSK has demonstrated, often respond remarkably well to immunotherapy alone, frequently allowing patients to forgo arduous treatments like surgery, chemotherapy, and radiation. The inability of checkpoint inhibitors to effectively treat MSS/MMRp colorectal cancer has left a significant treatment gap, making this particular subtype a high-priority target for innovative therapeutic development. The SKI team’s deep dive into this challenging landscape holds immense promise for a large proportion of colorectal cancer patients.
Two Types of Treg Cells with Opposing Effects: A Detailed Unveiling
To decipher the unique immunological profile of common colorectal cancers, the research team employed a sophisticated mouse model meticulously developed at MSK. This model faithfully recapitulates the genetic alterations, behavioral characteristics, and complex immune microenvironment observed in human colorectal tumors, providing a robust platform for mechanistic investigation.
Through a series of rigorous experiments and meticulous analysis, the researchers made a pivotal discovery: tumor-associated Treg cells are not uniform but can be distinctly categorized into two primary groups based on their cytokine production profiles. One group actively produces a key signaling molecule, or cytokine, known as interleukin-10 (IL-10), while the other does not.
By selectively removing each of these Treg groups in a controlled experimental setting, the team uncovered profound and contrasting effects on tumor growth:
-
IL-10-positive Treg cells: The Guardians Against Tumor Growth. These cells emerged as beneficial actors, playing a crucial role in slowing tumor progression. Their protective mechanism involves reducing the activity of Th17 cells, another type of immune cell that produces interleukin 17 (IL-17). IL-17 is known to act as a potent growth signal for tumors, promoting their proliferation and survival. By dampening Th17 activity and subsequent IL-17 production, IL-10-positive Tregs effectively put a brake on tumor expansion. Intriguingly, these protective Treg cells were found to be more abundantly located in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining tissue homeostasis and potentially preventing tumor invasion into surrounding areas. The experimental evidence was compelling: when IL-10-positive Treg cells were selectively depleted, tumors in the mouse model grew significantly more quickly, underscoring their critical inhibitory role.
-
IL-10-negative Treg cells: The Immune Suppressors Within the Tumor. In stark contrast, the IL-10-negative Treg cells exhibited a detrimental effect, actively fueling tumor growth by suppressing powerful immune defenders. Specifically, these cells were found to inhibit the activity of CD8+ T cells, which are renowned for their potent cancer-fighting abilities, often referred to as "killer T cells." By silencing these crucial immune effectors, IL-10-negative Tregs create an immunosuppressive environment that allows the tumor to evade detection and destruction. This harmful subtype was predominantly located within the tumor itself, strategically positioned to neutralize anti-tumor responses. The experimental results were equally clear: when IL-10-negative Treg cells were eliminated, tumors in the mouse model significantly shrank, demonstrating their role as key enablers of tumor progression.
Patient Data Confirms the Findings: A Translational Validation
The strength of these findings was further solidified by their meticulous validation using human tumor samples. The research team meticulously analyzed biopsies from individuals diagnosed with colorectal cancer, confirming the presence of these two distinct populations of IL-10-positive and IL-10-negative Treg cells within human tumors, mirroring their observations in the mouse model.
Beyond cellular identification, the team delved into patient outcomes, analyzing data from over 100 colorectal cancer patients. The clinical correlation was striking: patients whose tumors exhibited higher levels of the beneficial IL-10-positive Treg cells consistently demonstrated longer overall survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer outcomes, reinforcing the direct clinical relevance of the preclinical findings.
"This research shows how important these positive cells are," affirms Dr. Huang. "And it highlights the urgent need to develop therapies that can selectively eliminate the harmful Tregs while carefully preserving the helpful ones. A blanket approach that targets all Tregs could inadvertently remove the protective cells, worsening outcomes."
This dual nature of Treg cells in colorectal cancer provides a long-awaited answer to the field’s enduring question and profoundly reshapes our understanding of the immune response in this disease. It also lays a robust foundation for a new era of highly targeted immunotherapies.
Targeting CCR8 as a New Treatment Strategy
The implications of these findings extend directly to the development of novel therapeutic strategies for the majority of colorectal cancer patients. A critical piece of the puzzle emerged when the researchers identified a distinguishing marker for the harmful Treg subtype. They discovered that IL-10-negative Treg cells, the ones primarily responsible for suppressing anti-tumor immunity and predominantly located within tumors, express high levels of a specific protein called CCR8.
This finding aligns perfectly with earlier, foundational work from Dr. Rudensky’s lab, notably led by breast cancer surgeon George Plitas, MD. That research had previously demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. This prior work had already suggested the exciting possibility of using CCR8-depleting antibodies to selectively remove these harmful Treg cells. The premise is compelling: by precisely eliminating only the detrimental Tregs, the immune system’s intrinsic ability to attack tumors could be unleashed more effectively, all while safeguarding the beneficial Treg cells that contribute to overall immune balance and potentially tumor suppression.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," states Dr. Rudensky. The convergence of this prior research with the new colorectal cancer findings significantly strengthens the rationale for this therapeutic approach.
Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this innovative strategy. These trials are exploring CCR8-targeting antibodies both as standalone treatments and in combination with existing immunotherapies, aiming to amplify their efficacy and overcome current resistance mechanisms. The new study provides compelling evidence that this strategy holds immense promise for colorectal cancer patients and potentially for a broader spectrum of other solid tumors.
Similar Immune Patterns in Other Cancers: Broader Therapeutic Horizons
The research team further explored the universality of their discovery by examining a vast dataset of T cells derived from 16 different cancer types. Their analysis revealed that the same distinct divisions between IL-10-positive and IL-10-negative Treg cells, with their opposing roles, were not unique to colorectal cancer. Similar immune patterns were identified in several other cancers affecting critical "barrier tissues," including the skin and the delicate linings of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explains Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This commonality suggests a fundamental immunological principle at play in cancers arising in these specific anatomical locations.
This broader applicability indicates that therapeutic strategies designed to remove IL-10-negative Treg cells, initially developed for colorectal cancer, could potentially be effective against these other barrier tissue cancers. This dramatically expands the potential impact of the current findings, offering hope for a wider range of patients facing challenging diagnoses.
A Different Immune Balance in Metastatic Disease: Nuances for Treatment
While the study offers profound insights into primary colorectal tumors, it also highlights the critical importance of considering disease stage. When the researchers investigated colorectal cancer that had metastasized, specifically to the liver, they observed a significantly different immune pattern.
In these metastatic tumors, the harmful IL-10-negative Treg cells dramatically outnumbered the beneficial IL-10-positive cells. Unlike the primary tumors, where selective targeting was paramount, removing all Treg cells in this metastatic context actually caused the tumors to shrink. This suggests that in advanced, metastatic disease, the overall balance of Tregs shifts decisively towards immune suppression, making a more generalized depletion of these cells a viable and potentially more effective strategy.
This crucial distinction underscores the necessity for highly tailored treatment approaches that account for both the specific tissue involved and the precise stage of the disease. A "one-size-fits-all" approach to Treg modulation may be insufficient, emphasizing the need for precision oncology that considers the dynamic immune landscape across different disease contexts.
Conclusion and Future Directions
The MSK study marks a monumental step forward in our understanding of colorectal cancer immunology. By definitively resolving the paradox of Treg cells in this disease, the research team has not only provided a clear scientific explanation but also illuminated a compelling path toward more effective, targeted immunotherapies. The identification of CCR8 as a specific marker for harmful Treg cells, coupled with the ongoing development of CCR8-depleting antibodies, offers a tangible and immediate avenue for clinical translation.
This work exemplifies the power of decades of foundational research converging with cutting-edge experimental and computational approaches to deliver impactful clinical insights. As clinical trials progress, the hope is that these innovative, selective approaches to modulating Treg cell populations will significantly improve outcomes for millions of patients battling colorectal cancer and potentially other challenging malignancies of barrier tissues. The future of cancer immunotherapy, increasingly precise and personalized, looks brighter thanks to this transformative discovery.
Authors, Funding, and Disclosures
Additional authors who contributed significantly to this comprehensive research include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional resources played vital roles in the execution of this research, including the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, which provided invaluable technological support and expertise.
Funding for this pivotal study was generously provided by multiple esteemed organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
Dr. Rudensky serves on various scientific advisory boards and holds equity in several biotechnology companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and contributes as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Crucially, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies against CCR8. These disclosures highlight the potential for direct translation of their scientific discoveries into clinical applications.
About the Author
